36. Epidermolysis bullosa Clinical trials / Disease details

Clinical trials : 160 / Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04644627 (ClinicalTrials.gov)	December 1, 2020	20/11/2020	Topical Gentamicin Nonsense Suppression Therapy of EB	TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONS	Epidermolysis Bullosa	Drug: Gentamicin Sulfate	Oslo University Hospital	NULL	Recruiting	N/A	N/A	All	6	Phase 1/Phase 2	Norway
2	EUCTR2020-002337-15-NO (EUCTR)	16/09/2020	29/06/2020	TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA	TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONS (THE GENTELBULL STUDY) - GENTELBULL	Epidermolysis bullosa caused by nonsense mutations or splice site mutations;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]	Trade Name: Infectogenta Product Name: Gentamicin sulfate 0.1% ointment	Oslo University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	6	Phase 2	Norway
3	NCT04140786 (ClinicalTrials.gov)	October 31, 2019	23/10/2019	Optimizing IV Gentamicin in JEB	Optimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients With Nonsense Mutations	Junctional Epidermolysis Bullosa	Drug: Gentamicin Sulfate, Injectable	University of Southern California	NULL	Recruiting	N/A	N/A	All	6	Phase 1/Phase 2	United States
4	NCT03526159 (ClinicalTrials.gov)	June 1, 2018	17/4/2018	Gentamicin for Junctional Epidermolysis Bullosa	A Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin Treatment	Junctional Epidermolysis Bullosa	Drug: Gentamicin Sulfate	University of Southern California	NULL	Recruiting	N/A	N/A	All	6	Phase 1/Phase 2	United States
5	NCT03012191 (ClinicalTrials.gov)	February 2, 2017	4/1/2017	Gentamicin for RDEB	Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense Mutations	Recessive Dystrophic Epidermolysis Bullosa	Drug: Gentamicin Sulfate	University of Southern California	NULL	Completed	N/A	N/A	All	6	Phase 1/Phase 2	United States